WO2026022741 - ACOLTREMON COMBINATIONS WITH LIFITEGRAST OR CYCLOSPORIN AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/022741
Publication Date
29.01.2026
International Application No.
PCT/IB2025/057483
International Filing Date
23.07.2025
Title **
[English]
ACOLTREMON COMBINATIONS WITH LIFITEGRAST OR CYCLOSPORIN AND USES THEREOF
[French]
COMBINAISONS D'ACOLTRÉMON AVEC DU LIFITEGRAST OU DE LA CYCLOSPORINE ET LEURS UTILISATIONS
Applicants **
ALCON INC.
Inventors
KABRA, Bhagwati P.
RAPPON, Joseph Michael
Priority Data
63/674,707
23.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2258 | |
| EPO | Filing, Examination, Granting | 12222 | |
| Japan | Filing, Examination, Granting | 2408 | |
| South Korea | Filing, Examination, Granting | 2553 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
25,381
Contact Us
Abstract[English]
Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.[French]
La présente invention concerne des combinaisons comprenant : 1) de l'acoltrémon; et 2) du lifitegrast ou de la cyclosporine, ou un sel pharmaceutiquement acceptable de ceux-ci. Les combinaisons sont utiles pour traiter la sécheresse oculaire ou le syndrome lacrymal dysfonctionnel, ou un signe ou symptôme de ceux-ci.